Table 2 Baseline characteristics in matched population
| Â | Non-DM patients | DM patients | Standardized difference (%) |
|---|---|---|---|
Age (years) | 75 [74 to 75] | 75 [74 to 76] | 2.7 |
Male sex | 84.5% [81.8% to 87.1%] | 84.2% [79.4% to 88.9%] | 0.8 |
Smoking | |||
 Never | 22.3% [19.2% to 25.4%] | 22.3% [16.8% to 27.7%] | 0.4 |
 Past | 60.6% [57.0% to 64.2%] | 59.6% [53.2% to 66.0%] | 1.9 |
 Current | 17.1% [14.3% to 19.9%] | 18.1% [13.1% to 23.1%] | 2.6 |
Pack-years of smoking | |||
 None | 22.6% [19.4% to 25.7%] | 22.5% [17.1% to 28.0%] | 0.5 |
 > 0 and ≤ 20 pack-years | 11.6% [9.2% to 14.0%] | 11.6% [7.0% to 16.3%] | 2.4 |
 > 20 and ≤ 40 pack-years | 22.1% [18.9% to 25.4%] | 22.5% [16.9% to 28.2%] | 1.4 |
 > 40 pack-years | 43.7% [39.9% to 47.6%] | 43.3% [36.7% to 49.9%] | 1.7 |
BMI | |||
 < 20 kg/m2 | 11.9% [9.5% to 14.3%] | 11.8% [7.6% to 16.0%] | 0.4 |
 20 to 25 kg/m2 | 58.5% [54.9% to 62.2%] | 57.9% [51.5% to 64.4%] | 1.3 |
 ≥ 25 kg/m2 | 29.6% [26.2% to 32.9%] | 30.3% [24.3% to 36.3%] | 1.6 |
Hypertension | 90.4% [88.2% to 92.5%] | 91.0% [87.2% to 94.7%] | 2.0 |
Dyslipidemia | 85.6% [83.0% to 88.2%] | 86.4% [82.0% to 90.9%] | 2.4 |
Renal failure on dialysis | 3.7% [2.3% to 5.1%] | 4.5% [1.8% to 7.2%] | 4.0 |
Chronic obstructive pulmonary disease | 34.7% [31.2% to 38.2%] | 33.9% [27.8% to 40.1%] | 1.6 |
Malignant neoplasm | |||
 None | 73.7% [70.5% to 77.0%] | 73.3% [67.5% to 79.1%] | 1.0 |
 Cured | 15.2% [12.6% to 17.9%] | 16.3% [11.5% to 21.1%] | 2.9 |
 In treatment | 11.0% [8.7% to 13.4%] | 10.4% [6.4% to 14.4%] | 2.0 |
Family history of aortic aneurysm | 3.7% [2.3% to 5.2%] | 3.6% [1.0% to 6.3%] | 2.2 |
Myocardial infarction | 16.5% [13.8% to 19.3%] | 17.6% [12.7% to 22.6%] | 3.0 |
History of coronary revascularization | 25.8% [22.5% to 29.0%] | 26.7% [20.9% to 32.5%] | 2.1 |
Cerebral hemorrhage | 4.3% [2.8% to 5.8%] | 4.1% [1.5% to 6.6%] | 1.1 |
Cerebral infarction | 13.9% [11.3% to 16.5%] | 14.5% [9.9% to 19.1%] | 1.8 |
LEAD | 11.3% [8.7% to 13.9%] | 13.5% [9.0% to 18.1%] | 6.8 |
Statin use | 56.6% [52.9% to 60.2%] | 58.3% [51.9% to 64.8%] | 3.5 |
Beta blocker use | 39.9% [36.3% to 43.5%] | 41.1% [34.7% to 47.5%] | 2.4 |
Renin-angiotensin system inhibitor use | 42.7% [39.0% to 46.4%] | 41.7% [35.2% to 48.1%] | 2.1 |
Antiplatelet use | 48.5% [44.8% to 52.2%] | 48.8% [42.2% to 55.4%] | 0.9 |
Anticoagulant use | 18.2% [15.3% to 21.1%] | 18.2% [13.2% to 23.3%] | 0.7 |
Systolic blood pressure | |||
 < 120 mmHg | 27.6% [24.3% to 30.9%] | 27.2% [21.4% to 33.1%] | 0.8 |
 120 to 140 mmHg | 48.0% [44.3% to 51.7%] | 48.2% [41.7% to 54.8%] | 0.6 |
 140 to 160 mmHg | 18.8% [15.9% to 21.7%] | 18.2% [13.1% to 23.2%] | 1.5 |
 ≥ 160 mmHg | 5.6% [3.9% to 7.3%] | 6.3% [3.2% to 9.5%] | 3.2 |
Diastolic blood pressure | |||
 < 80 mmHg | 63.4% [59.8% to 67.0%] | 63.3% [57.0% to 69.6%] | 0.5 |
 80 to 90 mmHg | 22.6% [19.5% to 25.7%] | 21.8% [16.4% to 27.2%] | 2.1 |
 90 to 100 mmHg | 10.9% [8.6% to 13.2%] | 11.8% [7.6% to 16.0%] | 3.0 |
 ≥ 100 mmHg | 3.1% [1.8% to 4.4%] | 3.2% [0.9% to 5.5%] | 0.5 |
Non-HDL cholesterol | |||
 < 100 mg/dl (< 2.59 mmol/l) | 24.8% [21.3% to 28.3%] | 25.8% [19.9% to 31.7%] | 2.7 |
 100 to 130 mg/dl (2.59 to 3.36 mmol/l) | 31.9% [28.2% to 35.7%] | 31.5% [24.9% to 38.1%] | 2.6 |
 130 to 170 mg/dl (3.36 to 4.40 mmol/l) | 31.1% [27.3% to 34.9%] | 31.5% [24.9% to 38.1%] | 2.8 |
 ≥ 170 mg/dl (≥ 4.40 mmol/l) | 12.2% [9.6% to 14.8%] | 11.1% [6.9% to 15.4%] | 3.3 |
LDL cholesterol | |||
 < 70 mg/dl (< 1.81 mmol/l) | 15.3% [12.5% to 18.0%] | 14.9% [9.9% to 19.9%] | 2.4 |
 70 to 100 mg/dl (1.81 to 2.59 mmol/l) | 35.7% [32.1% to 39.3%] | 37.3% [30.7% to 43.9%] | 3.7 |
 100 to 140 mg/dl (2.59 to 3.62 mmol/l) | 36.6% [33.0% to 40.3%] | 36.7% [30.4% to 43.0%] | 0.7 |
 ≥ 140 mg/dl (≥ 3.62 mmol/l) | 12.4% [9.9% to 14.9%] | 11.1% [6.9% to 15.4%] | 3.9 |
HDL cholesterol | |||
 < 40 mg/dl (< 1.03 mmol/l) | 28.6% [25.1% to 32.1%] | 28.6% [22.3% to 34.9%] | 2.1 |
 40 to 50 mg/dl (1.03 to 1.29 mmol/l) | 33.7% [29.8% to 37.5%] | 34.8% [28.3% to 41.2%] | 2.7 |
 50 to 60 mg/dl (1.29 to 1.55 mmol/l) | 18.6% [15.1% to 22.0%] | 18.1% [12.8% to 23.5%] | 2.1 |
 ≥ 60 mg/dl (≥ 1.55 mmol/l) | 19.2% [16.0% to 22.3%] | 18.5% [13.2% to 23.8%] | 2.3 |
Triglycerides | |||
 < 100 mg/dl (< 1.13 mmol/l) | 31.3% [27.7% to 34.8%] | 31.6% [25.4% to 37.8%] | 1.3 |
 100 to 150 mg/dl (1.13 to 1.69 mmol/l) | 31.5% [28.0% to 35.0%] | 32.1% [25.8% to 38.3%] | 1.7 |
 150 to 200 mg/dl (1.69 to 2.26 mmol/l) | 21.6% [18.4% to 24.7%] | 20.7% [15.2% to 26.1%] | 2.6 |
 ≥ 200 mg/dl (≥ 2.26 mmol/l) | 15.7% [12.9% to 18.4%] | 15.7% [10.9% to 20.4%] | 0.8 |
Estimated glomerular filtration rate | |||
 < 15 ml/min/1.73 m2 | 5.0% [3.3% to 6.6%] | 5.4% [2.5% to 8.4%] | 2.1 |
 15 to 30 ml/min/1.73 m2 | 6.9% [5.0% to 8.8%] | 6.8% [3.5% to 10.1%] | 0.4 |
 30 to 60 ml/min/1.73 m2 | 49.4% [45.7% to 53.1%] | 49.8% [43.3% to 56.3%] | 0.7 |
 ≥ 60 ml/min/1.73 m2 | 38.7% [35.1% to 42.4%] | 38.0% [31.7% to 44.3%] | 1.5 |
LVEF | |||
 < 50% | 9.2% [7.0% to 11.4%] | 9.3% [5.4% to 13.1%] | 1.1 |
 50% to 60% | 17.8% [14.9% to 20.8%] | 18.8% [13.6% to 24.0%] | 2.5 |
 60% to 70% | 57.5% [53.5% to 61.4%] | 57.0% [50.4% to 63.6%] | 1.3 |
 ≥ 70% | 15.5% [12.6% to 18.4%] | 14.9% [10.1% to 19.8%] | 2.2 |